Target intelligence / Profile preview

Microbiome-mediated immune modulation

Molecular classification
Other (not a receptor, enzyme, etc.)
01

Overview

Microbiome-mediated immune modulation refers to the collective influence of the commensal microbiota on the development, function, and regulation of the host immune system. Microbial organisms in the gut and other barrier sites interact with immune cells through their metabolites, conserved structural components, and signaling pathways, shaping both innate and adaptive immune responses. This interaction helps maintain tolerance to harmless antigens, fine-tune barrier immunity, and calibrate responses to pathogens. Disruption of microbiome composition has been associated with increased risk of autoimmune, inflammatory, infectious, and even cancer-related diseases.

Other names
Microbiota-immune interactionGut microbiota immune modulationMicrobiome-immune crosstalk
02

Mechanism of action

Modulation of cytokine production (e.g., IL-22, IL-1β); Induction of regulatory T cells (Tregs); Production of microbial metabolites (e.g., short-chain fatty acids, SCFAs) that affect immune cells; Interaction with host pattern recognition receptors (PRRs), such as Toll-like receptors (TLR5, TLR9) and Nod-like receptors

03

Biological functions

Regulation of immune responsesMaintenance of mucosal and systemic immune homeostasisInduction of tolerance to harmless antigensModulation of inflammatory and anti-inflammatory processes
04

Disease associations

InflammationAutoimmune diseases (e.g., IBD, type 1 diabetes)Cancer (tumor immunity and response to immunotherapy)InfectionOther immune-mediated diseases
05

Safety considerations

Dysbiosis may contribute to or exacerbate autoimmune and inflammatory diseasesAlteration of microbiota with antibiotics, probiotics, or transplantation may cause adverse immune effects or infections
06

Interacting drugs

Probiotics (e.g., *Bifidobacterium* spp., *Lactobacillus* spp.)

3 more in the full profile.

07

Biomarkers

Microbiome composition (identified by 16S rRNA sequencing)Levels of specific microbial metabolites (e.g., SCFA concentrations)IgA coating of gut bacteria

Beyond the preview

Go deeper on Microbiome-mediated immune modulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbiome-mediated immune modulation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call